To address growing demand from customers in continental Europe, the company is building a medical manufacturing facility in Katowice, Poland
Phillips-Medisize, a Molex company and provider of drug delivery, diagnostic and MedTech devices, has announced the expansion of its global manufacturing footprint, along with extended product design, development and manufacturing capabilities. The company's global reach now encompasses 36 facilities with end-to-end capabilities.
"As the preferred partner for leading global customers, we continually invest in new talent and technologies that increase the capacity and capabilities of Phillips-Medisize across the entire value chain," said Paul Chaffin, President, Medical and Pharmaceutical Solutions, Molex. "Our expanded global reach and resources will enable us to solve complex development and manufacturing challenges while meeting escalating customer demands for more localised production, supply chain management and accelerated go-to-market strategies."
To address growing demand from customers in continental Europe, the company is building a medical manufacturing facility in Katowice, Poland. Slated to open in 2022, the site will complement production sites and centres in Asia, Europe, India, Mexico and North America. The company is also expanding production capacity in Suzhou, China to serve both global and regional pharmaceutical and medtech customers. Additionally, the transformation of an existing Molex production facility in Little Rock, Ark., is underway, enabling Phillips-Medisize to keep pace with ever-increasing requirements in the U.S. for high-volume, diagnostic device manufacturing.
Once these expansions are complete, the company will offer nearly three million sqft of country- and region-specific manufacturing space and R&D capabilities worldwide. The company also will support 600,000 sqft of Class 7 and 8 cleanrooms, which complement existing tool building sites as well as global quality and regulatory systems. In 2020, the company completed a facility in Wisconsin, with 285,000 sqft supporting production of molded components for medical diagnostic customers requiring high-volume assembly and packaging of regulated products. The facility also includes a nearly 64,000 sqft ISO 14644-1 Class 8 cleanroom.
Strategic investments in talent acquisition to support the company's continued growth are expected to add at least 1,000 employees worldwide over the next couple of years.
"We're excited to leverage Phillips-Medisize's world-class manufacturing as we scale toward high-volume automation at the new state-of-the-art facility in Poland," said Jeff Tillack, COO at Credence MedSystems. "The opportunity to scale production in close proximity to our operations and European customers will accelerate market delivery of our innovative solutions to meet the needs of our pharma customers and their end-users."
In September, GlucoModicum entered into a design and development program with Phillips-Medisize for the rapid scale-up of manufacturing for its Talisman needle-free continuous glucose monitor, which uses magnetohydrodynamic (MHD) technology. Also last month, Paris-based Eyevensys announced an engagement with Phillips-Medisize to optimise the design, development and high-volume manufacturing of its ocular device component that powers the delivery of novel gene therapies for treating various eye diseases.